Synthesis and Antitumour Evaluation of Tricyclic Indole‐2‐Carboxamides against Paediatric Brain Cancer Cells

Abstract Antitumour properties of some cannabinoids (CB) have been reported in the literature as early as 1970s, however there is no clear consensus to date on the exact mechanisms leading to cancer cell death. The indole‐based WIN 55,212‐2 and SDB‐001 are both known as potent agonists at both CB 1 and CB 2 receptors, yet we demonstrate herein that only the former can exert in vitro antitumour effects when tested against a paediatric brain cancer cell line KNS42. In this report, we describe the synthesis of novel 3,4‐fused tricyclic indoles and evaluate their functional potencies at both cannabinoid receptors, as well as their abilities to inhibit the growth or proliferation of KNS42 cells. Compared to our previously reported indole‐2‐carboxamides, these 3,4‐fused tricyclic indoles had either completely lost activities, or, showed moderate‐to‐weak antagonism at both CB 1 and CB 2 receptors. Compound 23 displayed the most potent antitumour properties among the series. Our results further support the involvement of non‐CB pathways for the observed antitumour activities of amidoalkylindole‐based cannabinoids, in line with our previous findings. Transcriptomic analysis comparing cells treated or non‐treated with compound 23 suggested the observed antitumour effects of 23 are likely to result mainly from disruption of the FOXM1‐regulated cell cycle pathways.